PD-L1 immune checkpoint inhibitors can effectively treat cancer by inhibiting or blocking the binding between PD-1 and PD-L1, allowing the patients to regain its immune function to recognize and kill cancer cells, thus achieving the satisfactory therapeutic effect. Here, CD274 is linked to cancer.